Skip to content

GlobalLawDBby GenieAI

Laws Search Sanctions Map Data Developers

Search the text of the law

Log in Get an API key

Laws Search Sanctions Map Data Developers

Log in Get an API key

The Global Law Database. Free to read, built for people and AI agents.

Explore

All laws
Search the text
Sanctions
Map of connections
Compare UK and EU

Developers

AI agents (MCP)
REST API
Bulk data
API keys

Coverage

United Kingdom
European Union
United States
Canada
Australia
France
Germany
Netherlands
Spain
Austria
Norway
Finland
Switzerland
Ireland

GlobalLawDB is made by GenieAI, London. It is not legal advice: check the official text before relying on it. Text comes from official publishers under their licences, listed on the Data page.

ThemeMatch my systemLightDark

European Union
MPA Pharma GmbH v Rhône-Poulenc Pharma GmbH (C-232/94)
Judgment
23

MPA Pharma GmbH v Rhône-Poulenc Pharma GmbH (C-232/94)

Judgment of 11 Jul 1996law://eu/cjeu/1994/c-232-94/para_23@2026-11-11

23That case-law must, however, be clarified further in the light of the arguments raised in these cases, and in Bristol-Myers Squibb, cited above, and Joined Cases C-71/94, C-72/94 and C-73/94 Eurim-Pharm v Beiersdorf and Others, in which the Court has also given judgment today.

Source: EUR-Lex, © European Union, 1998-2026. Reuse authorised under Decision 2011/833/EU.

Key facts

Court: Court of Justice · Full Court
Case: C-232/94 · ECLI:EU:C:1996:289
Decided: 11 Jul 1996
Procedure: Preliminary reference
Applicant: MPA Pharma GmbH
Defendant: Rhône-Poulenc Pharma GmbH
Rapporteur: C. Gulmann
Advocate General: F. G. Jacobs
Bench: 8 judges
C. N. Kakouris, J.-P Puissochet, G. Hirsch (Presidents of Chambers), G. E Mancini, J. C. Moitinho de Almeida, C. Gulmann, P. Jann, H. Ragnemalm
Language: German
Official: CURIA · EUR-Lex 61994CJ0232

Topics

Measures having equivalent effect System of property ownership

History · 1 version

11 Jul 1996Reading

Connections

Interprets 1: Treaty on the Functioning of the European Union (consolidated 2016)2 provisions
Cited by 6: Bristol-Myers Squibb v Paranova A/S and C. H. Boehringer Sohn, Boehringer Ingelheim KG and Boehringer Ingelheim A/S v Paranova A/S and Bayer Aktiengesellschaft and Bayer Danmark A/S v Paranova A/S (C-427/93, C-429/93, C-436/93)2 provisions; Orifarm A/S and Others and Paranova Danmark A/S and Paranova Pack A/S v Merck Sharp & Dohme Corp. and Merck Sharp & Dohme BV and Merck Sharp & Dohme (C-400/09, C-207/10)2 provisions; Aventis Pharma Deutschland GmbH v Kohlpharma GmbH and MTK Pharma Vertriebs-GmbH (C-433/00)3 provisions; Pharmacia & Upjohn SA v Paranova A/S (C-379/97); Frits Loendersloot, trading as F. Loendersloot Internationale Expeditie v George Ballantine & Son Ltd and Others (C-349/95)2 provisions; Eurim-Pharm Arzneimittel GmbH v Beiersdorf AG, Boehringer Ingelheim KG and Farmitalia Carlo Erba GmbH (C-71/94, C-72/94, C-73/94)2 provisions
Cites 12: Treaty on the Functioning of the European Union (consolidated 2016)2 provisions; Bristol-Myers Squibb v Paranova A/S and C. H. Boehringer Sohn, Boehringer Ingelheim KG and Boehringer Ingelheim A/S v Paranova A/S and Bayer Aktiengesellschaft and Bayer Danmark A/S v Paranova A/S (C-427/93, C-429/93, C-436/93); Marleasing SA v La Comercial Internacional de Alimentacion SA (C-106/89); Paola Faccini Dori v Recreb Srl (C-91/92); First Council Directive 89/104/EEC of 21 December 1988 to approximate the laws of the Member States relating to trade marks; M. H. Marshall v Southampton and South-West Hampshire Area Health Authority (Teaching) (152/84); Centrafarm BV and Adriaan de Peijper v Winthrop BV (16/74); Hoffmann-La Roche & Co. AG v Centrafarm Vertriebsgesellschaft Pharmazeutischer Erzeugnisse mbH (102/77); Pfizer Inc. v Eurim-Pharm GmbH (1/81); Eurim-Pharm Arzneimittel GmbH v Beiersdorf AG, Boehringer Ingelheim KG and Farmitalia Carlo Erba GmbH (C-71/94, C-72/94, C-73/94); IHT Internationale Heiztechnik GmbH and Uwe Danzinger v Ideal-Standard GmbH and Wabco Standard GmbH (C-9/93); SA CNL-SUCAL NV v HAG GF AG (C-10/89)